Partial lecithin:cholesterol acyltransferase (LCAT) deficiency in Balkan endemic nephropathy.
Nephropathy of familial lecithin-cholesterol acyltransferase deficiency: report of a case.
Possible association between an abnormal low density lipoprotein and nephropathy in lecithin: cholesterol acyltransferase deficiency.
Two novel variants in the lecithin:cholesterol acyltransferase gene resulted in classic LCAT deficiency.
Fistrek Prlic M, Coric M, Calabresi L, Pavanello C, Mosca L, Cavallari U, Vukovic Brinar I, Karanovic S, Laganovic M, Jelakovic B.
Atheroscler Plus. 2022 Jun 2;49:28-31. doi: 10.1016/j.athplu.2022.05.005. eCollection 2022 Aug.
Novel therapeutic opportunities for familial lecithin:cholesterol acyltransferase deficiency: promises and challenges.
Vitali C, Rader DJ, Cuchel M.
Curr Opin Lipidol. 2023 Apr 1;34(2):35-43. doi: 10.1097/MOL.0000000000000864. Epub 2022 Dec 6.
Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome.
Vaziri ND, Liang K, Parks JS.
Am J Physiol Renal Physiol. 2001 May;280(5):F823-8. doi: 10.1152/ajprenal.2001.280.5.F823.
[Glomerulopathy associated with lecithin-cholesterol-acyltransferase deficiency: A case report and literature review].
Delteil C, Macagno N, Appay R, Uzan M, Jourde-Chiche N, Daniel L.
Ann Pathol. 2019 Apr;39(2):172-176. doi: 10.1016/j.annpat.2018.09.005. Epub 2018 Dec 12.
[Lecithin:Cholesterol Acyltransferase Deficiency, from genes to therapy].
Lucca F, Ossoli A, Boscutti G, Franceschini G, Calabresi L.
G Ital Nefrol. 2016 Malattie Metaboliche e Rene;33(S68):gin/33.S68.3.
High-Density Lipoproteins and the Kidney.
Strazzella A, Ossoli A, Calabresi L.
Cells. 2021 Mar 31;10(4):764. doi: 10.3390/cells10040764.
Lecithin: cholesterol acyltransferase (LCAT) deficiency syndromes.
Frohlich J, McLeod R.
Adv Exp Med Biol. 1986;201:181-94. doi: 10.1007/978-1-4684-1262-8_16.
AJKD Atlas of Renal Pathology: Lecithin-Cholesterol Acyltransferase (LCAT) Deficiency.
Najafian B, Lusco MA, Finn LS, Alpers CE, Fogo AB.
Am J Kidney Dis. 2017 Jul;70(1):e5-e6. doi: 10.1053/j.ajkd.2017.05.003.
Acquired lecithin:cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease.
Calabresi L, Simonelli S, Conca P, Busnach G, Cabibbe M, Gesualdo L, Gigante M, Penco S, Veglia F, Franceschini G.
J Intern Med. 2015 May;277(5):552-61. doi: 10.1111/joim.12290. Epub 2014 Aug 1.
LCAT- targeted therapies: Progress, failures and future.
Yang K, Wang J, Xiang H, Ding P, Wu T, Ji G.
Biomed Pharmacother. 2022 Mar;147:112677. doi: 10.1016/j.biopha.2022.112677. Epub 2022 Feb 2.
